

In recent years, the pharmaceutical industry has faced significant challenges regarding the availability and quality of raw materials. Factors such as geopolitical tensions, trade restrictions, and the COVID-19 pandemic have disrupted supply chains, leading to shortages of essential APIs and raw materials. This situation has spotlighted the need for greater resilience and diversification of supply sources. Companies are now encouraged to consider multiple suppliers and invest in local sourcing to mitigate risks associated with disruptions.
Clinical studies have highlighted the benefits of LOLA in patients with chronic liver disease. For instance, several trials have demonstrated that LOLA treatment can lead to significant reductions in ammonia levels, accompanied by improvements in cognitive function and overall quality of life for patients suffering from hepatic encephalopathy. This therapeutic potential positions LOLA as a viable option for managing complications arising from chronic liver diseases, particularly in cases where standard treatments may be insufficient.